Compugen Ltd. (NASDAQ:CGEN) – Equities researchers at FBR & Co issued their Q1 2017 earnings per share (EPS) estimates for Compugen in a research note issued on Tuesday. FBR & Co analyst V. Bernardino anticipates that the brokerage will post earnings of ($0.15) per share for the quarter. FBR & Co also issued estimates for Compugen’s Q2 2017 earnings at ($0.16) EPS, Q3 2017 earnings at ($0.16) EPS, Q4 2017 earnings at ($0.15) EPS and FY2019 earnings at $0.59 EPS.

Compugen (NASDAQ:CGEN) last posted its quarterly earnings data on Monday, November 7th. The company reported ($0.15) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.14) by $0.01. Compugen had a negative net margin of 261.77% and a negative return on equity of 28.19%.

Earnings History and Estimates for Compugen (NASDAQ:CGEN)

Separately, Zacks Investment Research raised Compugen from a “hold” rating to a “buy” rating and set a $7.00 price objective for the company in a report on Tuesday, October 4th. Six analysts have rated the stock with a buy rating, The stock currently has an average rating of “Buy” and an average price target of $10.40.

Shares of Compugen (NASDAQ:CGEN) opened at 6.25 on Wednesday. Compugen has a one year low of $4.32 and a one year high of $7.79. The firm’s 50 day moving average is $6.13 and its 200-day moving average is $6.61. The firm’s market capitalization is $318.18 million.

Several hedge funds have recently made changes to their positions in CGEN. BlackRock Fund Advisors boosted its stake in shares of Compugen by 4.6% in the third quarter. BlackRock Fund Advisors now owns 671,557 shares of the company’s stock worth $4,231,000 after buying an additional 29,402 shares during the period. Stockman Asset Management bought a new stake in shares of Compugen during the third quarter worth approximately $597,000. Benjamin F. Edwards & Company Inc. boosted its stake in shares of Compugen by 88.0% in the third quarter. Benjamin F. Edwards & Company Inc. now owns 47,650 shares of the company’s stock worth $300,000 after buying an additional 22,300 shares during the period. ProShare Advisors LLC boosted its stake in shares of Compugen by 0.8% in the second quarter. ProShare Advisors LLC now owns 37,652 shares of the company’s stock worth $244,000 after buying an additional 300 shares during the period. Finally, Vident Investment Advisory LLC bought a new stake in shares of Compugen during the second quarter worth approximately $522,000. 14.11% of the stock is owned by institutional investors.

Compugen Company Profile

Compugen Ltd. (Compugen) is a therapeutic discovery company. The Company focuses on the discovery and development of monoclonal antibodies (mAbs) and therapeutic proteins in the fields of oncology and immunology. Its pipeline program consists of drug targets and therapeutic product candidates at various stages ranging from target validation to pre-clinical studies in the fields of oncology and immunology, with a primary focus on immuno-oncology.

5 Day Chart for NASDAQ:CGEN

Receive News & Stock Ratings for Compugen Ltd. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Compugen Ltd. and related stocks with our FREE daily email newsletter.